Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on August 13, 2009. The filing announces the company's financial results for the quarter ended June 30, 2009. The report includes a press release as Exhibit 99.1 but explicitly states that the information is not deemed "filed" under Section 18 of the Exchange Act.
Key Financial Metrics
The provided text serves as a cover document referencing a press release but does not contain specific financial data. Consequently, the filing text does not provide clear values for:
- Revenue
- Profit or Net Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not disclose specific material changes in financial condition or operations compared to prior periods. It only confirms the issuance of a press release regarding the Q2 2009 results.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the press release (Exhibit 99.1) contains the results but does not summarize its content within the 8-K body.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual revenue, loss, and cash position figures for the quarter ended June 30, 2009.
- Confirm that the financial data in the press release is not incorporated by reference into other registration statements unless expressly stated.
- Check for any subsequent filings that may provide updated liquidity or debt status.